Page last updated: 2024-09-05

lenalidomide and Venous Thromboembolism

lenalidomide has been researched along with Venous Thromboembolism in 35 studies

Research

Studies (35)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (11.43)29.6817
2010's22 (62.86)24.3611
2020's9 (25.71)2.80

Authors

AuthorsStudies
Baljevic, M; Callander, NS; Castillo, JJ; Hillengass, J; Kumar, SK; Lim, MY; Martin, T; Sborov, DW; Streiff, MB1
Attal, M; Chalayer, E; Collet, P; Frenzel, L; Guyotat, D; Karlin, L; Leleu, X; Talbot, A; Tardy, B1
Anderson, LD; Baljevic, M; Bartlett, JB; Chari, A; Cortoos, A; Costa, LJ; Efebera, YA; Holstein, SA; Kaufman, JL; Laubach, J; Lin, TS; Patel, S; Pei, H; Reeves, B; Richardson, PG; Rodriguez, C; Sborov, DW; Shah, N; Silbermann, R; Vermeulen, J; Voorhees, PM1
Fiala, MA; Kavanaugh, M; Loncharich, AJ; Sanfilippo, KM; Schroeder, MA; Slade, MJ; Stockerl-Goldstein, K; Vickroy, A; Vij, R; Wilson, C1
Cheng, Q; Hu, Y; Li, J; Li, Q; Sun, C; Xu, A; Yan, H; Zhang, B; Zhao, F1
Anwer, F; Bin Riaz, I; Chakraborty, R; Khan, SU; Khorana, AA; Kumar, S; Majhail, NS; Malik, SU; Marneni, N; Mejia Garcia, A; Murad, MH; Rajkumar, SV; Wang, Z1
Cornell, RF; Engelhardt, BG; Goldhaber, SZ; Hall, R; Harrell, S; Jagasia, M; Moslehi, J; Piazza, G; Rubinstein, SM; Wyatt, H1
Bradbury, CA; Cairns, DA; Child, JA; Cook, G; Craig, Z; Davies, FE; Drayson, MT; Gregory, WM; Hockaday, A; Jackson, GH; Jenner, MW; Jones, JR; Kaiser, MF; Morgan, GJ; Owen, RG; Paterson, A; Pawlyn, C1
Derkach, A; Hassoun, H; Hultcrantz, M; Korde, N; Lesokhin, A; Lu, S; Mailankody, S; Orozco, J; Patel, D; Peterson, T; Piedra, K; Shah, U; Tan, C; Wilkins, CR1
Anderson, SM; Beck, B; Lockhorst, R; Ngorsuraches, S; Sterud, S1
Orna, E; Sancho, JM; Sorigue, M1
Christos, PJ; Demetres, M; Hammad, H; Leonard, JP; Ruan, J; Yamshon, S1
Bang, SM; Jo, JC; Kim, JS; Kim, K; Lee, HS; Lee, JJ; Lee, JO; Lee, YJ; Min, CK; Shin, J; Suh, C; Yoon, SS1
Auger-Quittet, S; Bareau, B; Belhadj-Merzoug, K; Benboubker, L; Bosson, JL; Boyle, E; Cliquennois, M; Decaux, O; Fuzibet, JG; Karlin, L; Leleu, X; Leyronnas, C; Orsini-Piocelle, F; Pegourie, B; Pernod, G; Rey, P; Rodon, P; Royer, B; Slama, B; Tiab, M; Voog, E; Zarnitsky, C1
Isoda, A; Koumoto, M; Matsumoto, M; Matsumoto, Y; Miyazawa, Y; Ookawa, M; Sato, N; Sawamura, M1
Kawaguchi, M; Konuma, S; Nehashi, Y; Okuda, Y; Uchimura, N1
Chaturvedi, S; Mohty, M; Nagler, A; Neff, A; Savani, BN; Savani, U1
Al-Ani, F; Bermejo, JM; Louzada, M; Mateos, MV1
Hamahata, K; Nohgawa, M; Oka, S; Shiragami, H; Takeuchi, S1
Lentzsch, S; Raza, S; Safyan, RA1
Dahdaleh, FS; Musallam, KM; Shamseddine, AI; Taher, AT1
Wiernik, PH1
Brandenburg, NA; Bwire, R; Freeman, J; Knight, RD; Salomon, ML; Yang, X; Zeldis, JB1
Dimopoulos, MA; Fink, L; Finlayson, A; Fu, T; Knight, R; Niesvizky, R; Polavaram, L; Tricot, G; Weber, D; Zangari, M; Zhan, F1
Hassett, AC; Lentzsch, S; List, A; Mapara, MY; Monaghan, SA; Moscinski, L; Pal, R; Ragni, MV; Roodman, GD; Schafer, P1
Mateos, MV1
Kristinsson, SY1
Carrier, M; Le Gal, G; Lee, AY; Tay, J; Wu, C1
González Rodríguez, AP1
García Sánchez, PJ; González Rodríguez, AP; Mesa, MG; Pérez Persona, E1
Brioli, A; Cavo, M; Pantani, L; Tacchetti, P; Zamagni, E; Zannetti, B1
Beggiato, E; Boccadoro, M; Bringhen, S; Cafro, AM; Carella, AM; Catalano, L; Cavalli, M; Cavallo, F; Cavo, M; Corradini, P; Crippa, C; Di Raimondo, F; Di Toritto, TC; Evangelista, A; Falanga, A; Larocca, A; Nagler, A; Palumbo, A; Patriarca, F; Peccatori, J; Petrucci, MT; Pezzatti, S; Siniscalchi, A; Stanevsky, A; Yehuda, DB1
Ay, C; Pabinger, I; Thaler, J1
Anderson, KC; Bradwin, G; Connell, B; Doyle, M; Ghobrial, I; Hong, F; Lockridge, L; Mitsiades, C; Munshi, N; Richardson, P; Rosovsky, R; Schlossman, R; Soiffer, RJ; Tocco, D; Warren, D; Weller, E1
Anderson, KC; Attal, M; Barlogie, B; Belch, A; Bladé, J; Boccadoro, M; Bringhen, S; Cavo, M; Dimopoulos, MA; Durie, BG; Harousseau, J; Hussein, MA; Joshua, D; Knop, S; Kyle, R; Lonial, S; Ludwig, H; Morgan, GJ; Niesvizky, R; Orlowski, RZ; Palumbo, A; Rajkumar, SV; Richardson, PG; San Miguel, J; Sezer, O; Shimizu, K; Sonneveld, P; Vesole, D; von Lilienfeld-Toal, M; Waage, A; Weber, D; Westin, J; Zangari, M; Zonder, JA1

Reviews

15 review(s) available for lenalidomide and Venous Thromboembolism

ArticleYear
Optimizing Thromboembolism Prophylaxis for the Contemporary Age of Multiple Myeloma.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2022, Volume: 20, Issue:1

    Topics: Anticoagulants; Humans; Lenalidomide; Multiple Myeloma; Risk Factors; Thalidomide; Venous Thromboembolism

2022
Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis.
    Cancer, 2020, 04-15, Volume: 126, Issue:8

    Topics: Angiogenesis Inhibitors; Anticoagulants; Dexamethasone; Humans; Incidence; Lenalidomide; Multiple Myeloma; Venous Thromboembolism

2020
Venous thromboembolism in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with lenalidomide: a systematic review.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:11

    Topics: Angiogenesis Inhibitors; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Meta-Analysis as Topic; Prognosis; Prospective Studies; Venous Thromboembolism

2018
Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis.
    Blood advances, 2018, 06-26, Volume: 2, Issue:12

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunologic Factors; Lenalidomide; Lymphoma, B-Cell; Multiple Myeloma; Venous Thromboembolism

2018
Venous thromboembolism in hematopoietic stem cell transplant recipients.
    Bone marrow transplantation, 2016, Volume: 51, Issue:4

    Topics: Allografts; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Postoperative Complications; Thalidomide; Venous Thromboembolism

2016
Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review.
    Thrombosis research, 2016, Volume: 141

    Topics: Anti-Inflammatory Agents; Anticoagulants; Aspirin; Dexamethasone; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Risk; Thalidomide; Venous Thromboembolism

2016
Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
    Current cancer drug targets, 2017, Volume: 17, Issue:9

    Topics: Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Quality of Life; Thalidomide; Venous Thromboembolism

2017
Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.
    Thrombosis research, 2009, Volume: 123, Issue:5

    Topics: Arsenic Trioxide; Arsenicals; Aspirin; Boronic Acids; Bortezomib; Heparin, Low-Molecular-Weight; Humans; Incidence; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide; Venous Thromboembolism

2009
Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).
    Current treatment options in oncology, 2009, Volume: 10, Issue:1-2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Salvage Therapy; Thalidomide; Venous Thromboembolism; Young Adult

2009
Management of treatment-related adverse events in patients with multiple myeloma.
    Cancer treatment reviews, 2010, Volume: 36 Suppl 2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disorders of Excessive Somnolence; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Venous Thromboembolism

2010
Thrombosis in multiple myeloma.
    Hematology. American Society of Hematology. Education Program, 2010, Volume: 2010

    Topics: Humans; Lenalidomide; Multiple Myeloma; Risk Factors; Thalidomide; Thrombosis; Venous Thromboembolism

2010
Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.
    Journal of thrombosis and haemostasis : JTH, 2011, Volume: 9, Issue:4

    Topics: Cohort Studies; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Venous Thromboembolism

2011
Management of the adverse effects of lenalidomide in multiple myeloma.
    Advances in therapy, 2011, Volume: 28 Suppl 1

    Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Dose-Response Relationship, Drug; Gastrointestinal Diseases; Humans; Infections; Lenalidomide; Multiple Myeloma; Neutropenia; Practice Guidelines as Topic; Renal Insufficiency; Thalidomide; Thrombocytopenia; Treatment Outcome; Venous Thromboembolism

2011
Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:6

    Topics: Antineoplastic Agents; Fibrinolytic Agents; Humans; Lenalidomide; Models, Biological; Multiple Myeloma; Neoplasms; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Thalidomide; Venous Thromboembolism

2012
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
    Leukemia, 2008, Volume: 22, Issue:2

    Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Lenalidomide; Multiple Myeloma; Premedication; Risk Assessment; Risk Factors; Thalidomide; Thrombosis; Venous Thromboembolism; Warfarin

2008

Trials

7 trial(s) available for lenalidomide and Venous Thromboembolism

ArticleYear
Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: Lessons from the substudy of IFM/DFCI 2009 cohort.
    Journal of thrombosis and haemostasis : JTH, 2022, Volume: 20, Issue:8

    Topics: Anticoagulants; Bortezomib; Dexamethasone; gamma-Globulins; Humans; Lenalidomide; Multiple Myeloma; Venous Thromboembolism

2022
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.
    British journal of haematology, 2022, Volume: 199, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Aspirin; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Transplantation, Autologous; Venous Thromboembolism

2022
Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.
    British journal of haematology, 2020, Volume: 190, Issue:4

    Topics: Aged; Comorbidity; Consolidation Chemotherapy; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Myocardial Infarction; Pilot Projects; Proof of Concept Study; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridones; Stroke; Thalidomide; Thrombophilia; Venous Thromboembolism; Venous Thrombosis

2020
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
    Blood, 2020, 08-27, Volume: 136, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Incidence; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Progression-Free Survival; Risk Assessment; Thalidomide; Thrombophilia; Thrombosis; Transplantation, Autologous; Venous Thromboembolism; Vincristine

2020
Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study.
    American journal of hematology, 2019, Volume: 94, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Pyrazoles; Pyridones; Thalidomide; Venous Thromboembolism

2019
Silent venous thromboembolism in multiple myeloma patients treated with lenalidomide.
    International journal of hematology, 2015, Volume: 102, Issue:3

    Topics: Aged; Aged, 80 and over; Female; Fibrin Fibrinogen Degradation Products; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Thalidomide; Venous Thromboembolism

2015
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
    Blood, 2012, Jan-26, Volume: 119, Issue:4

    Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Enoxaparin; Female; Humans; Incidence; Israel; Italy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Platelet Aggregation Inhibitors; Pulmonary Embolism; Risk Factors; Thalidomide; Venous Thromboembolism; Venous Thrombosis

2012

Other Studies

13 other study(ies) available for lenalidomide and Venous Thromboembolism

ArticleYear
Venous Thromboembolism Risk in Patients With Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone.
    Clinical lymphoma, myeloma & leukemia, 2023, Volume: 23, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Retrospective Studies; Venous Thromboembolism

2023
Hematologists' awareness of venous thromboembolism in multiple myeloma: a national survey in China.
    Annals of medicine, 2023, Volume: 55, Issue:2

    Topics: Anticoagulants; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Venous Thromboembolism

2023
Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.
    British journal of haematology, 2022, Volume: 196, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Bortezomib; Dexamethasone; Disease Management; Disease Susceptibility; Female; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neoplasm Staging; Oligopeptides; Retrospective Studies; Venous Thromboembolism

2022
Evaluating the use of appropriate anticoagulation with lenalidomide and pomalidomide in patients with multiple myeloma.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2019, Volume: 25, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pulmonary Embolism; Retrospective Studies; Thalidomide; Venous Thromboembolism

2019
Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone.
    International journal of hematology, 2019, Volume: 109, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Retrospective Studies; Risk Factors; Salvage Therapy; Survival Analysis; Venous Thromboembolism

2019
[Successful treatment of venous thromboembolism with a Factor Xa inhibitor, edoxaban, in patients with lenalidomide-treated multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2015, Volume: 56, Issue:8

    Topics: Aged; Factor Xa Inhibitors; Female; Humans; Lenalidomide; Multiple Myeloma; Pyridines; Thalidomide; Thiazoles; Tomography, X-Ray Computed; Venous Thromboembolism

2015
Successful management of venous thromboembolism with apixaban in a multiple myeloma patient on lenalidomide therapy.
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2017, Volume: 58, Issue:1

    Topics: Aged; Factor Xa Inhibitors; Humans; Lenalidomide; Male; Multiple Myeloma; Pyrazoles; Pyridones; Thalidomide; Treatment Outcome; Venous Thromboembolism

2017
Venous thromboembolism in myelodysplastic syndrome patients receiving lenalidomide: results from postmarketing surveillance and data mining techniques.
    Clinical drug investigation, 2009, Volume: 29, Issue:3

    Topics: Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Databases, Factual; Erythropoiesis; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Product Surveillance, Postmarketing; Pulmonary Embolism; Risk Assessment; Thalidomide; United States; United States Food and Drug Administration; Venous Thromboembolism

2009
Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jan-01, Volume: 28, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Randomized Controlled Trials as Topic; Retrospective Studies; Thalidomide; Venous Thromboembolism

2010
Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia.
    Blood, 2010, Jan-21, Volume: 115, Issue:3

    Topics: Antineoplastic Agents; Cell Differentiation; Cells, Cultured; Down-Regulation; Granulocyte Colony-Stimulating Factor; Granulocyte Precursor Cells; Granulocytes; Humans; Immunologic Factors; Lenalidomide; Models, Biological; Multiple Myeloma; Myeloid Progenitor Cells; Neutropenia; Neutrophils; Platelet Aggregation; Proto-Oncogene Proteins; Risk Factors; Thalidomide; Trans-Activators; Venous Thromboembolism

2010
Lenalidomide treatment for patients with multiple myeloma: diagnosis and management of most frequent adverse events.
    Advances in therapy, 2011, Volume: 28 Suppl 1

    Topics: Adrenal Insufficiency; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Bence Jones Protein; Calcium; Dose-Response Relationship, Drug; Drug Dosage Calculations; Female; Hematologic Diseases; Humans; Lenalidomide; Male; Middle Aged; Monitoring, Physiologic; Multiple Myeloma; Patient Selection; Radiography; Thalidomide; Time; Treatment Outcome; Venous Thromboembolism

2011
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
    Seminars in thrombosis and hemostasis, 2011, Volume: 37, Issue:3

    Topics: Activated Protein C Resistance; Aged; Anticoagulants; Aspirin; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunologic Factors; International Normalized Ratio; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Risk Factors; Thalidomide; Thrombosis; Venous Thromboembolism; Warfarin

2011
Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study.
    British journal of haematology, 2013, Volume: 160, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Blood Coagulation; Blood Coagulation Factors; Cluster Analysis; Dexamethasone; Endothelial Cells; Female; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Stress, Physiological; Thalidomide; Venous Thromboembolism

2013
chemdatabank.com